Arkolith/Insider Trading/ORIC/Form 4

Kunkel Lori Anne

DirectorOric Pharmaceuticals, Inc. (ORIC) · full profile →Form 4 · filed Mar 4, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2025Option exercise(M)21K$6.33$130K69K
Mar 3, 2025Option exercise(M)28K$3.75$104K48K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 3, 2025Option exercise(M)28K—$06K
Mar 3, 2025Option exercise(M)21K—$00

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-006616) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML